The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Hepatitis C infection can be cured by using highly effective, simple, recently developed medications. This fellowship will explore new modes of delivering hepatitis C treatment outside of traditional hospital clinics. It will also explore the potential for successful treatment to prevent transmission of the hepatitis C. The fellowship will involve the first clinical trial of its type, along with modelling the benefits and cost-effectiveness of treatment and prevention.
Population-level Epidemiological Trends In Hepatocellular Carcinoma In Queensland 1996 - 2010.
Funder
National Health and Medical Research Council
Funding Amount
$251,695.00
Summary
Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC t ....Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC trends.Read moreRead less
Hepatitis C Treatment-as-prevention In The Prison Setting
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The burden of hepatitis C virus (HCV) infection in Australia is rising with prison settings being a major reservoir of HCV infection. This study evaluates the feasibility of a rapid scale-up of a new highly effective, short and tolerable HCV therapy and its impact on HCV transmission in the prison setting. This is the first HCV treatment-as-prevention study in prisons having strong potentials to inform public health policy nationally and internationally.
A Whole Genome Association Study For Determinants Of Clinical Outcome And Treatment Response In Chronic Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$360,133.00
Summary
Chronic hepatitis C infection (CHC) causes liver failure, liver cancer and death. The treatment response rate is poor. Understanding of the factors that increase an individual’s risk of developing serious liver disease, or that lead to treatment failure, is limited. This project, the first of its kind, will involve screening 1600 CHC patients for genes that are associated with disease outcome and treatment response, to identify novel targets for drug and vaccine development
Role Of TNF-á In Growth, Lineage Commitment And Differentiation Of Liver Progenitor Cells
Funder
National Health and Medical Research Council
Funding Amount
$228,589.00
Summary
The infection rate of HBV is 20% in Chinese and 10% in Australian in particularly aboriginal. The end-point of this disease is development liver failure and need functional replacement of the liver. Cell therapy represents an alternative of liver transplantation owing to shortage of organ. The information derived from this study is essential for developing strategies to promote growth and differentiation of liver progenitor cell both in vivo and in vitro for therapies to treat liver diseases.
Injecting Drug Use, Incarceration, Infection: Investigating Opportunities For Public Health Interventions In Disadvantaged Populations
Funder
National Health and Medical Research Council
Funding Amount
$329,564.00
Summary
New knowledge required to address infectious diseases and mental illness among two disadvantaged and overlapping groups -people who inject drugs (PWID) and prisoners – will be produced: Cross sectional and longitudinal studies will examine HIV risk in specific populations; A system to track the emergence of injecting will be developed; The global scale of mental illness and TB among PWID will be determined; and how to improve coverage and delivery of TB prevention and treatment will be explored.